Carisma Therapeutics Inc

Carisma Therapeutics Inc(CARM)の株式分析

$0.154

-0.067 (-43.81%)終値時点

Loading chart…
High
0.170
Open
0.159
VWAP
0.16
Vol
17.54M
Mkt Cap
53.17M
Low
0.147
Amount
2.75M
EV/EBITDA, TTM
0.00

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. The Company seeks to apply the ability to engineer macrophages and monocytes, either in vivo or ex vivo. Its proprietary chimeric antigen receptor macrophages(CAR-M) platform uses CARs to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted antitumor immunity. It is developing a pipeline of product candidates which includes CT-1119, In Vivo CAR-Macrophage: GPC3+ Solid Tumors, In Vivo CAR-Macrophage: Oncology Targets, and CT-2401 (Liver Fibrosis). CT-2401 is a product candidate in development for liver fibrosis, and CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.

sesenbio.com

バリュエーション指標

The current forward P/E ratio for Carisma Therapeutics Inc (CARM) is -0.38, compared to its 5-year average forward P/E of -1.34.

Forward P/E

Overvalued
5Y Average P/E
-1.34
Current P/E
-0.38
割高
-0.48
割安
-2.20

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
割高
0.00
割安
0.00

Forward P/S

Fair
5Y Average P/S
9.54
Current P/S
0.77
割高
22.91
割安
-3.82

Alphio AI Price Scenarios for CARM

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%CARM

$0.26

シナリオ価格

B

Base

Base · 50%CARM

$0.24

シナリオ価格

B

Bear

Bear · 25%CARM

$0.18

シナリオ価格

イベントタイムライン

2026-06-02 (ET)

08:20:00

ProKidney Appoints Kenneth Locke as Chief Technical Officer

2025-12-05 (ET)

11:30:00

Carisma Therapeutics to Voluntarily Delist and Terminate Reporting Obligations

2025-06-23 (ET)

07:33:47

Carisma Therapeutics, OrthoCellix enter definitive merger agreement

2024-12-09 (ET)

07:34:24

Carisma Therapeutics announces restructuring, 34% workforce reduction

2024-11-08 (ET)

06:33:44

Carisma Therapeutics reports data from its CAR-M therapy

ニュース

CARM FAQ — answered by Alphio AI

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. The Company seeks to apply the ability to engineer macrophages and monocytes, either in vivo or ex vivo. Its proprietary chimeric antigen receptor macrophages(CAR-M) platform uses CARs to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted antitumor immunity. It is developing a pipeline of product candidates which includes CT-1119, In Vivo CAR-Macrophage: GPC3+ Solid Tumors, In Vivo CAR-Macrophage: Oncology Targets, and CT-2401 (Liver Fibrosis). CT-2401 is a product candidate in development for liver fibrosis, and CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める